Verity Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Verity Asset Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.84M	Buy	30,333 +2,023	+7%	+$118K	0.77%	40
2025 Q4	$1.53M	Sell	28,310 -21,112	-43%	-$1.02M	0.66%	44
2025 Q3	$2.23M	Buy	49,422 +29,734	+151%	+$1.39M	0.73%	35
2025 Q2	$911K	Sell	19,688 -17,450	-47%	-$857K	0.44%	58
2025 Q1	$2.27M	Buy	37,138 +18,931	+104%	+$1.1M	0.92%	23
2024 Q4	$1.01M	Sell	18,207 -12,135	-40%	-$678K	0.57%	48
2024 Q3	$1.57M	Buy	30,342 +14,694	+94%	+$689K	0.59%	43
2024 Q2	$650K	Buy	15,648 +9,436	+152%	+$422K	0.25%	89
2024 Q1	$337K	Buy	6,212 +315	+5%	+$16K	0.19%	133
2023 Q4	$303K	Buy	5,897 +1,000	+20%	+$52.5K	0.19%	131
2023 Q3	$284K	Sell	4,897 -914	-16%	-$56K	0.21%	125
2023 Q2	$372K	Sell	5,811 -4,923	-46%	-$330K	0.28%	98
2023 Q1	$744K	Buy	10,734 +5,417	+102%	+$382K	0.44%	68
2022 Q4	$383K	Sell	5,317 -1,340	-20%	-$101K	0.33%	98
2022 Q3	$473K	Buy	+6,657	New	+$483K	0.49%	74
2022 Q1	$464K	Buy	+6,352	New	+$427K	0.29%	104
2016 Q3	$1.28M	Buy	+23,682	New	+$1.52M	1.19%	29

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Verity Asset Management's BMY Position: Q1 2026 in Review

Verity Asset Management increased its Bristol-Myers Squibb (BMY) stake by 7.1% in Q1 2026, buying an estimated $118K and bringing the position to 30,333 shares worth $1.84M. The position accounts for 0.77% of the portfolio, ranked #40.

Verity Asset Management first reported a position in BMY in Q3 2016 and has held it in 17 quarters since. The position peaked at $2.27M in Q1 2025. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Verity Asset Management held 30,333 shares of Bristol-Myers Squibb worth $1.84M as of Q1 2026.
Verity Asset Management bought 2,023 Bristol-Myers Squibb shares in Q1 2026, an estimated $118K.
Bristol-Myers Squibb made up 0.77% of Verity Asset Management's portfolio in Q1 2026, its #40 holding.
Verity Asset Management first reported a position in Bristol-Myers Squibb in Q3 2016 and has held it in 17 quarters since.
Verity Asset Management's Bristol-Myers Squibb position peaked at $2.27M in Q1 2025.
2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Verity Asset Management's 13F filing for Q1 2026, filed 21 Apr 2026.